Novo Nordisk Outlines Likely COVID-19 Crisis Trial Impacts
Group Heralds Semaglutide’s Positive Phase II NASH Outcome
Novo Nordisk said late stage clinical trials near completion would not be hit by the pandemic but that delays to other stage studies were likely, and new ones were now “on hold.”
You may also be interested in...
Experts think GLP-1s in neurodegeneration may be Novo Nordisk’s next opportunity and await readouts from the Phase II ELAD trial in Alzheimer's disease for signals.
Shrinking cash and COVID-19 uncertainty have prompted Nordic Nanovector to slash costs and focus purely on its lead asset’s pivotal trial in third-line follicular lymphoma.
Sanofi to sell most of its Regeneron stake, with much of it being re-purchased by Regeneron, but both stressed the move would not hurt their long established and very profitable drug-development collaboration.